Serial No. 09/200,791

wherein the pharmaceutically acceptable salts and carboxyl derivatives of poly-Dlysine or poly-L-lysine have a molecular weight in the range 1-60 kD,

whereby said compound or compounds reduce kidney retention of said conjugates.

- 2. (Amended) A method according to claim 1, wherein said protein conjugate is selected from the group consisting of protein conjugates, peptide conjugates, polypeptide conjugates, glycoprotein conjugates, lipoprotein conjugates, antibody conjugates[,] and antibody fragment conjugates [and the metabolic products thereof].
- (Amended) A method of reducing kidney retention of a protein conjugate in a 18. patient undergoing treatment with a targeting protein conjugate comprising administering to said patient, one or more compounds selected from the group consisting of D-lysine, poly-Dlysine having a molecular weight in the range 1/60 kD, poly-L-lysine having a molecular weight in the range 1-60 kD, pharmaceutically acceptable salts thereof and carboxyl derivatives thereof, wherein said protein conjugate has a molecular weight that is not greater than about 60 kD,

wherein the pharmaceutically acceptable salts and carboxyl derivatives of poly-Dlysine or poly-L-lysine have a molecular weight in the range 1-60 kD,

whereby said compound or compounds reduce kidney retention of said conjugates.

19. (Amended) A method according to claim 18, wherein said protein conjugate is selected from the group consisting of protein conjugates, peptide conjugates, polypeptide conjugates, glycoprotein conjugates, lipoprotein conjugates, antibody conjugates[,] and antibody fragment conjugates [and the metabolic products thereof].

- 22. (Amended) A method according to claim 21, wherein said ribonuclease is an [onconase] ONCONASE [or recombinant form thereof].
- 24. (Amended) A method according to claim [22] 23, wherein the radiolabel in said radiolabeled conjugates is an imaging isotope.

Serial No. 09/200,791

(Amended) A method according to claim [22] 23, wherein the radiolabel in said radiolabeled conjugates is a therapeutic isotope.

Claim 36, line 5, change "carrier "to -- carrier. --.